These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 38968945)

  • 1. Stability of Bas-Congo virus neutralising antibodies in serum samples during long-term storage-Authors' reply.
    Munyeku-Bazitama Y; Okitale-Talunda P; Hattori T; Saito T; Lombe BP; Miyamoto H; Mori-Kajihara A; Kajihara M; Nkoy AB; Tshibwabwa Twabela A; Masumu J; Ahuka-Mundeke S; Muyembe-Tamfum JJ; Igarashi M; Park ES; Morikawa S; Makiala-Mandanda S; Takada A
    Lancet Microbe; 2024 Oct; 5(10):100917. PubMed ID: 38968945
    [No Abstract]   [Full Text] [Related]  

  • 2. Stability of Bas-Congo virus neutralising antibodies in serum samples during long-term storage.
    Cong Y; Zhao Y; Zhao L; Wang Y; Zhang F; Zhao J
    Lancet Microbe; 2024 Oct; 5(10):100916. PubMed ID: 38968946
    [No Abstract]   [Full Text] [Related]  

  • 3. Seroprevalence of Bas-Congo virus in Mangala, Democratic Republic of the Congo: a population-based cross-sectional study.
    Munyeku-Bazitama Y; Okitale-Talunda P; Hattori T; Saito T; Lombe BP; Miyamoto H; Mori-Kajihara A; Kajihara M; Nkoy AB; Twabela AT; Masumu J; Ahuka-Mundeke S; Muyembe-Tamfum JJ; Igarashi M; Park ES; Morikawa S; Makiala-Mandanda S; Takada A
    Lancet Microbe; 2024 Jun; 5(6):e529-e537. PubMed ID: 38555924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stablity of yellow fever virus neutralising antibody titres - Authors' reply.
    Domingo C; Bhat N; Ansah P; Mejía JE
    Lancet Infect Dis; 2020 Feb; 20(2):167. PubMed ID: 32006502
    [No Abstract]   [Full Text] [Related]  

  • 5. FluoRNT: A robust, efficient assay for the detection of neutralising antibodies against yellow fever virus 17D.
    Scheck MK; Lehmann L; Zaucha M; Schwarzlmueller P; Huber K; Pritsch M; Barba-Spaeth G; Thorn-Seshold O; Krug AB; Endres S; Rothenfusser S; Thorn-Seshold J
    PLoS One; 2022; 17(2):e0262149. PubMed ID: 35139078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.
    Kreuzberger N; Hirsch C; Chai KL; Tomlinson E; Khosravi Z; Popp M; Neidhardt M; Piechotta V; Salomon S; Valk SJ; Monsef I; Schmaderer C; Wood EM; So-Osman C; Roberts DJ; McQuilten Z; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013825. PubMed ID: 34473343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial.
    Ruckwardt TJ; Morabito KM; Phung E; Crank MC; Costner PJ; Holman LA; Chang LA; Hickman SP; Berkowitz NM; Gordon IJ; Yamshchikov GV; Gaudinski MR; Lin B; Bailer R; Chen M; Ortega-Villa AM; Nguyen T; Kumar A; Schwartz RM; Kueltzo LA; Stein JA; Carlton K; Gall JG; Nason MC; Mascola JR; Chen G; Graham BS;
    Lancet Respir Med; 2021 Oct; 9(10):1111-1120. PubMed ID: 33864736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two randomised, double-blind, multicentre, phase 3 trials.
    Mariz FC; Gray P; Bender N; Eriksson T; Kann H; Apter D; Paavonen J; Pajunen E; Prager KM; Sehr P; Surcel HM; Waterboer T; Müller M; Pawlita M; Lehtinen M
    Lancet Infect Dis; 2021 Oct; 21(10):1458-1468. PubMed ID: 34081923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Importance of dose of neutralising antibodies in treatment of Argentine haemorrhagic fever with immune plasma.
    Enria DA; Briggiler AM; Fernandez NJ; Levis SC; Maiztegui JI
    Lancet; 1984 Aug; 2(8397):255-6. PubMed ID: 6146809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study.
    Chia WN; Zhu F; Ong SWX; Young BE; Fong SW; Le Bert N; Tan CW; Tiu C; Zhang J; Tan SY; Pada S; Chan YH; Tham CYL; Kunasegaran K; Chen MI; Low JGH; Leo YS; Renia L; Bertoletti A; Ng LFP; Lye DC; Wang LF
    Lancet Microbe; 2021 Jun; 2(6):e240-e249. PubMed ID: 33778792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An HIV-1/HIV-2 Chimeric Envelope Glycoprotein Generates Binding and Neutralising Antibodies against HIV-1 and HIV-2 Isolates.
    Taveira N; Figueiredo I; Calado R; Martin F; Bártolo I; Marcelino JM; Borrego P; Cardoso F; Barroso H
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B cell immunodominance in primary hepatitis C virus infection.
    Brasher NA; Eltahla AA; Underwood A; Boo I; Rizzetto S; Walker MR; Rodrigo C; Luciani F; Maher L; Drummer HE; Tedla N; Lloyd AR; Bull RA
    J Hepatol; 2020 Apr; 72(4):670-679. PubMed ID: 31785346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Letter: biologics are effective in neutralising the detrimental effect of smoking on the natural course of Crohn's disease - authors' reply.
    To N; Gracie DJ; Ford AC
    Aliment Pharmacol Ther; 2016 Jun; 43(11):1246. PubMed ID: 27137735
    [No Abstract]   [Full Text] [Related]  

  • 14. Modification of the fluorescent antibody virus neutralisation test--elimination of the cytotoxic effect for the detection of rabies virus neutralising antibodies.
    Bedeković T; Lemo N; Lojkić I; Mihaljević Z; Jungić A; Cvetnić Z; Cač Z; Hostnik P
    J Virol Methods; 2013 Apr; 189(1):204-8. PubMed ID: 23403247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age related resistance to avian leukosis virus. III. Infectious virus, neutralising antibody and tumours in chickens inoculated at various ages.
    Maas HJ; De Boer GF; Groenendal JE
    Avian Pathol; 1982; 11(2):309-27. PubMed ID: 18770194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mineral Carbonation of Biomass Ashes in Relation to Their CO
    Vassilev SV; Vassileva CG; Petrova NL
    ACS Omega; 2021 Jun; 6(22):14598-14611. PubMed ID: 34124483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of the Bas-Congo virus glycoprotein and its function in pseudotyped viruses.
    Steffen I; Liss NM; Schneider BS; Fair JN; Chiu CY; Simmons G
    J Virol; 2013 Sep; 87(17):9558-68. PubMed ID: 23785218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis.
    Ciapponi A; Bardach A; Rey Ares L; Glujovsky D; Cafferata ML; Cesaroni S; Bhatti A
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD011260. PubMed ID: 31801180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced immunosurveillance for animal morbilliviruses using vesicular stomatitis virus (VSV) pseudotypes.
    Logan N; Dundon WG; Diallo A; Baron MD; James Nyarobi M; Cleaveland S; Keyyu J; Fyumagwa R; Hosie MJ; Willett BJ
    Vaccine; 2016 Nov; 34(47):5736-5743. PubMed ID: 27742221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stability of Chronic Hepatitis-Related Parameters in Serum Samples After Long-Term Storage.
    Yu R; Dan Y; Xiang X; Zhou Y; Kuang X; Yang G; Tang Y; Liu M; Kong W; Tan W; Deng G
    Biopreserv Biobank; 2017 Jun; 15(3):211-219. PubMed ID: 27960069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.